Search Press releases

Press releases teaser image
20 Mar 2026

Acquisition of own shares

Read More
Press releases teaser image
13 Mar 2026

Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees

Read More
Press releases teaser image
11 Mar 2026

BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50

Read More
Press releases teaser image
3 Mar 2026

UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody

Read More
Press releases teaser image
26 Feb 2026

Strong Execution Fueling Sustained Company Growth

Read More
Press releases teaser image
4 Feb 2026

UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe